| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies (NCT01823198) | M.D. Anderson Cancer Center | 2013-06-11 |
| Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment (NCT02099266) | University of Kansas Medical Center | 2013-06-01 |
| Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS (NCT01700673) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2013-06-01 |
| Metabolism Des LAM (NCT02176109) | University Hospital, Grenoble | 2013-06-01 |
| Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01804101) | Fred Hutchinson Cancer Center | 2013-05-07 |
| Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS (NCT02190695) | Fox Chase Cancer Center | 2013-04-01 |
| Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia (NCT01819792) | Centre Hospitalier Universitaire, Amiens | 2013-04-01 |
| Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients (NCT01838395) | BioLineRx, Ltd. | 2013-04-01 |
| Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML (NCT01830361) | Technische Universität Dresden | 2013-03-13 |
| Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML (NCT01794169) | Karolinska University Hospital | 2013-03-01 |
| Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor (NCT01794299) | Kiadis Pharma | 2013-03-01 |
| Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (NCT01819558) | Institut Paoli-Calmettes | 2013-03-01 |
| Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly (NCT02845232) | Hospices Civils de Lyon | 2013-03-01 |
| Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (NCT01802333) | National Cancer Institute (NCI) | 2013-02-12 |
| Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid Leukaemia (NCT01785953) | Azienda Ospedaliera San Giovanni Battista | 2013-02-01 |
| GRASPA Treatment for Patients With Acute Myeloblastic Leukemia (NCT01810705) | ERYtech Pharma | 2013-02-01 |
| Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT01829503) | Annie Im, M.D. | 2013-02-01 |
| Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65 (NCT02341495) | Elizabeth Henry | 2013-02-01 |
| GVAX vs. Placebo for MDS/AML After Allo HSCT (NCT01773395) | Dana-Farber Cancer Institute | 2013-01-08 |
| Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors (NCT01751997) | Byung-Sik Cho | 2013-01-01 |
| Samples From Leukemia Patients and Their Donors to Identify Specific Antigens (NCT02667093) | PersImmune, Inc | 2013-01-01 |
| Busulfan and Cyclophosphamide Followed By ALLO BMT (NCT01685411) | Masonic Cancer Center, University of Minnesota | 2013-01-01 |
| Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia (NCT02842112) | Hospices Civils de Lyon | 2013-01-01 |
| A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) (NCT01713582) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-12-14 |
| Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01701323) | Nohla Therapeutics, Inc. | 2012-12-10 |
| Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia (NCT01743859) | University of Colorado, Denver | 2012-12-06 |
| CNDO-109-AANK for AML in First Complete Remission (CR1) (NCT01520558) | Coronado Biosciences, Inc. | 2012-12-01 |
| Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant (NCT01720264) | Sherif S. Farag | 2012-11-02 |
| Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS) (NCT01770158) | University of Ulm | 2012-10-01 |
| Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission (NCT01686334) | Zwi Berneman | 2012-10-01 |
| Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms (NCT02084563) | Hospital Israelita Albert Einstein | 2012-10-01 |
| A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving (NCT01684150) | Epizyme, Inc. | 2012-09-01 |
| Mismatched Donor Cells to Treat Acute Myeloid Leukemia (NCT01793025) | Maisonneuve-Rosemont Hospital | 2012-09-01 |
| Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome (NCT01433965) | University of California, Davis | 2012-08-08 |
| Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation (NCT01615757) | All India Institute of Medical Sciences | 2012-08-01 |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies (NCT01606579) | Prism Pharma Co., Ltd. | 2012-07-01 |
| Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission (NCT01656252) | PrECOG, LLC. | 2012-07-01 |
| Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction (NCT01578954) | UNC Lineberger Comprehensive Cancer Center | 2012-06-28 |
| A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT01546038) | Pfizer | 2012-06-27 |
| Protocol in Acute Myeloid Leukemia With FLT3-ITD (NCT01477606) | University of Ulm | 2012-05-01 |
| A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia (NCT01358734) | Celgene | 2012-04-27 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning (NCT01572662) | M.D. Anderson Cancer Center | 2012-04-11 |
| Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia (NCT02034227) | Spirogen | 2012-04-01 |
| Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML) (NCT01488344) | University Hospital Muenster | 2012-03-01 |
| Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype (NCT01534260) | Hamid Sayar | 2012-02-10 |
| Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell (NCT01660607) | Stanford University | 2012-02-09 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients (NCT01489722) | AstraZeneca | 2012-02-01 |
| TevaGastrim for Stem Cell Mobilization Sibling Donors (NCT01542944) | Sheba Medical Center | 2012-02-01 |
| Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001) (NCT01475370) | Otsuka Pharmaceutical Co., Ltd. | 2012-01-24 |
| Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia (NCT01452646) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2012-01-01 |
| Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia (NCT01455025) | French Innovative Leukemia Organisation | 2012-01-01 |
| Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML (NCT01534702) | Hannover Medical School | 2012-01-01 |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome (NCT01463046) | University of California, San Francisco | 2012-01-01 |
| Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia (NCT01573247) | Akinion Pharmaceuticals AB | 2011-12-01 |
| Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy (NCT02860598) | Hospices Civils de Lyon | 2011-12-01 |
| Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT01349049) | Daiichi Sankyo | 2011-11-21 |
| Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia (NCT01420926) | National Cancer Institute (NCI) | 2011-11-16 |
| Administration of Donor T Cells With the Caspase-9 Suicide Gene (NCT01494103) | Baylor College of Medicine | 2011-11-01 |
| VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT01541280) | Nantes University Hospital | 2011-11-01 |
| ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia (NCT01478074) | Altor BioScience | 2011-11-01 |
| Study of the Predictive Marker FLT in Patients Suffering From AML (NCT01599429) | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 2011-10-31 |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies (NCT01461538) | Seagen Inc. | 2011-10-01 |
| A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01303796) | Cyclacel Pharmaceuticals, Inc. | 2011-10-01 |
| MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia (NCT01385787) | Center for International Blood and Marrow Transplant Research | 2011-10-01 |
| Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia (NCT01627041) | National Cancer Institute (NCI) | 2011-09-16 |
| Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy (NCT01334086) | University Health Network, Toronto | 2011-09-01 |
| A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients (NCT01440920) | Otsuka Pharmaceutical Co., Ltd. | 2011-09-01 |
| NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases (NCT01370213) | Masonic Cancer Center, University of Minnesota | 2011-09-01 |
| Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia (NCT00867672) | University Hospital Freiburg | 2011-08-01 |
| HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia (NCT01484171) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2011-08-01 |
| Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant (NCT01398501) | Massachusetts General Hospital | 2011-08-01 |
| Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01371981) | National Cancer Institute (NCI) | 2011-07-06 |
| A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) (NCT01305499) | Hetty Carraway | 2011-07-01 |
| ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS (NCT01423175) | Hannover Medical School | 2011-07-01 |
| Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (NCT01398462) | JW Pharmaceutical | 2011-07-01 |
| Preservation of Ovarian Function After Hematopoietic Cell Transplant (NCT01343368) | Masonic Cancer Center, University of Minnesota | 2011-07-01 |
| Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies (NCT01399840) | Pfizer | 2011-06-30 |
| Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) (NCT01352650) | Weill Medical College of Cornell University | 2011-06-17 |
| The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia (NCT01065545) | Northwestern University | 2011-06-01 |
| Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (NCT01361334) | University Hospital Muenster | 2011-06-01 |
| An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy (NCT01446081) | University Health Network, Toronto | 2011-06-01 |
| Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) (NCT02101983) | University of Rochester | 2011-05-01 |
| Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML) (NCT01329471) | Hillel Yaffe Medical Center | 2011-04-01 |
| Phase I Study of OPB-51602 in Patients With Hematologic Malignancies (NCT01344876) | Otsuka Pharmaceutical Co., Ltd. | 2011-04-01 |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia (NCT01297543) | Cellerant Therapeutics | 2011-03-01 |
| Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia (NCT01332786) | University Health Network, Toronto | 2011-03-01 |
| Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT01295307) | Technische Universität Dresden | 2011-03-01 |
| Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients (NCT01149408) | University of Utah | 2011-02-01 |
| Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant (NCT01252667) | Fred Hutchinson Cancer Center | 2011-01-25 |
| WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (NCT01266083) | Sellas Life Sciences Group | 2011-01-14 |
| Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML (NCT01277484) | Seoul St. Mary's Hospital | 2011-01-01 |
| Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR) (NCT01301820) | French Innovative Leukemia Organisation | 2011-01-01 |
| Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) (NCT01451268) | Johann Wolfgang Goethe University Hospital | 2011-01-01 |
| Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01280786) | Synta Pharmaceuticals Corp. | 2011-01-01 |
| Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01238211) | National Cancer Institute (NCI) | 2010-12-14 |
| Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients (NCT05188326) | Associazione Qol-one | 2010-11-28 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (NCT01231412) | Fred Hutchinson Cancer Center | 2010-11-01 |
| AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy (NCT02024308) | Changhai Hospital | 2010-11-01 |
| Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia (NCT01222143) | University Health Network, Toronto | 2010-10-01 |
| PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias (NCT01169012) | UNC Lineberger Comprehensive Cancer Center | 2010-09-01 |